Skip to content

Roivant Sciences ROIV Interest Expense

Discontinued — last reported Q1 '24

Interest Expense at other companies

Royalty Pharma logo
Royalty PharmaRPRX
$93.72M+43.6%
Incyte logo
IncyteINCY
$569K-13.8%
Viatris logo
ViatrisVTRS
$120.1M+4.0%
Amgen logo
AmgenAMGN
ALN
Alnylam PharmaceuticalsALNY
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Revenue$2.5M-66.7%

Balance sheet

See full
Cash & equivalents$1.4B+1,411%
Total debt$107.4M+7.3%
Total equity$4.5B-3.4%
Total assets$5.7B+5.0%

Cash flow

See full
Operating cash flow-$163.8M+5.1%
CapEx$1.3M+55.5%
Free cash flow-$165.1M+4.8%

Valuation

See full
Market cap$22.61B+175%
Enterprise value$21.29B+157%
P/S2,736.9×+2,454×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio18.4×-15.1×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:InterestExpense.

The official record: Roivant Sciences’s 10-Q, filed August 9, 2024, on SEC EDGAR. View the filing →

Ask your AI about Roivant Sciences's interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Roivant Sciences's interest expense?
Roivant Sciences (ROIV) reported interest expense of $13.4M in Q2 2024.
How has Roivant Sciences's interest expense changed year-over-year?
Roivant Sciences's interest expense increased by 50.3% year-over-year, from $8.91M to $13.4M.
What is the long-term trend for Roivant Sciences's interest expense?
Over 2 years (2021 to 2023), Roivant Sciences's interest expense has grown at a 122.2% compound annual growth rate (CAGR), from $7.04M to $34.78M.